fluorouracil has been researched along with Experimental Mammary Neoplasms in 183 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of this study was to elucidate whether hyperoxia also enhances any actual uptake of 5FU (5-fluorouracil) into the tumor tissue and if this can be explained by changes in the interstitium and extracellular matrix." | 7.75 | Hyperoxia increases the uptake of 5-fluorouracil in mammary tumors independently of changes in interstitial fluid pressure and tumor stroma. ( Kolmannskog, O; Moen, I; Reed, RK; Salvesen, GS; Stuhr, LE; Tronstad, KJ, 2009) |
| "The antitumor activity of 1-hexylcarbamoyl-5-fluorouracil (HCFU) in various schedules of long-term oral administration was examined in spontaneous mammary adenocarcinoma of SHN mice, an autochthonous tumor system." | 7.66 | Effect of 1-hexylcarbamoyl-5-fluorouracil on spontaneous mammary adenocarcinoma of mice. ( Hoshi, A; Iigo, M; Kuretani, K; Tokuzen, R, 1980) |
| "In two separate experiments, treatment of C3H/He mice bearing transplantable mammary adenocarcinomas (C3HBA) with a regimen of 6-propylthiouracil (PTUra) and 5-fluorouracil (FUra) plus chloroquine phosphate (CP) resulted in complete remissions of 77 and 65%, respectively." | 7.66 | Remissions of mammary adenocarcinoma in hypothyroid mice given 5-fluorouracil and chloroquine phosphate. ( Dagher, RK; Shoemaker, JP, 1979) |
| "Metastasizing mammary adenocarcinoma 13762 in female Fischer rats has been used as a model for studying postoperative adjuvant chemotherapy, using methotrexate (Mtx) and 5-fluouracil (5FU) either singly or in combinations." | 7.65 | Adjuvant postoperative chemotherapy with 5-fluorouracil and methotrexate: effect of schedule of administration on metastasis of 13762 mammary adenocarcinoma. ( Khwaja, TA; Lee, YT, 1977) |
| " This review focuses on the development and establishment of the Dark Agouti rat mammary adenocarcinoma model by the Mucositis Research Group of the University of Adelaide over the past 20 years to characterize the mechanisms underlying methotrexate-, 5-fluorouracil-, and irinotecan-induced mucositis." | 4.91 | Dark Agouti rat model of chemotherapy-induced mucositis: establishment and current state of the art. ( Bateman, E; Keefe, D; Mayo, B; Stringer, A; Thorpe, D; Vanhoecke, B; Vanlancker, E, 2015) |
| "Histological study of structural transformations in the thymus of Wistar females in induced carcinogenesis (N-methyl-N-nitrosourea injection in the right 2-nd mamma) and polychemotherapy (6 months after tumor growth initiation; cyclophosphamide, methotrexate, and 5-fluorouracyl) was carried out." | 3.85 | The Thymus in Experimental Mammary Carcinogenesis and Polychemotherapy. ( Ishchenko, IY; Kabakov, AV; Kazakov, OV; Konenkov, VI; Michurina, SV; Poveshchenko, AF; Raiter, TV; Strunkin, DN, 2017) |
| "BENSpm exhibited synergistic inhibitory effect on cell proliferation in combination with 5-FU or paclitaxel in human breast cancer cell lines (MDA-MB-231 and MCF-7) and was either antagonistic or less effective in the non-tumorigenic MCF-10A cell line." | 3.76 | The role of the polyamine catabolic enzymes SSAT and SMO in the synergistic effects of standard chemotherapeutic agents with a polyamine analogue in human breast cancer cell lines. ( Billam, M; Casero, RA; Davidson, NE; Hacker, A; Pledgie-Tracy, A; Sobolewski, MD; Woster, PM; Zhang, Z, 2010) |
| " The aim of this study was to elucidate whether hyperoxia also enhances any actual uptake of 5FU (5-fluorouracil) into the tumor tissue and if this can be explained by changes in the interstitium and extracellular matrix." | 3.75 | Hyperoxia increases the uptake of 5-fluorouracil in mammary tumors independently of changes in interstitial fluid pressure and tumor stroma. ( Kolmannskog, O; Moen, I; Reed, RK; Salvesen, GS; Stuhr, LE; Tronstad, KJ, 2009) |
| ") administration of 5-fluorouracil (5-FU) or 5-fluoro-2'-deoxyuridine (FUdR) in BDF1 mice bearing murine mammary adenocarcinoma 755 and athymic mice bearing the transplantable human colon adenocarcinoma LS174T." | 3.68 | Antitumor effect and tumor level of 5-fluoro-2'-deoxyuridylate following oral administration of tetradecyl 2'-deoxy-5-fluoro-5'-uridylate. ( Hoshi, A; Iigo, M; Nakajima, Y, 1992) |
| "2,2'-Anhydro-5-ethyluridine (ANEUR), a potent inhibitor of uridine phosphorylase, markedly potentiated the antitumor activity of fluorouridine (FUR) against murine mammary adenocarcinoma 755 in BDF1 mice and human colon adenocarcinoma LS174T in athymic-nude mice." | 3.68 | Differential effects of 2,2'-anhydro-5-ethyluridine, a uridine phosphorylase inhibitor, on the antitumor activity of 5-fluorouridine and 5-fluoro-2'-deoxyuridine. ( De Clercq, E; Iigo, M; Nakajima, Y; Nishikata, K; Szabolcs, A; Szinai, I; Veres, Z, 1990) |
| "The antitumor activity of 1-hexylcarbamoyl-5-fluorouracil (HCFU) in various schedules of long-term oral administration was examined in spontaneous mammary adenocarcinoma of SHN mice, an autochthonous tumor system." | 3.66 | Effect of 1-hexylcarbamoyl-5-fluorouracil on spontaneous mammary adenocarcinoma of mice. ( Hoshi, A; Iigo, M; Kuretani, K; Tokuzen, R, 1980) |
| "In two separate experiments, treatment of C3H/He mice bearing transplantable mammary adenocarcinomas (C3HBA) with a regimen of 6-propylthiouracil (PTUra) and 5-fluorouracil (FUra) plus chloroquine phosphate (CP) resulted in complete remissions of 77 and 65%, respectively." | 3.66 | Remissions of mammary adenocarcinoma in hypothyroid mice given 5-fluorouracil and chloroquine phosphate. ( Dagher, RK; Shoemaker, JP, 1979) |
| "Three distinct subpopulations of tumor cells derived from a single parent strain BALB/cfC3H mammary adenocarcinoma were tested in vivo for sensitivity to cyclophosphamide, methotrexate, and 5-fluorouracil." | 3.66 | Heterogeneity in drug sensitivity among tumor cell subpopulations of a single mammary tumor. ( Calabresi, P; DeNucci, T; Dexter, DL; Heppner, GH; Miller, FR, 1978) |
| "Metastasizing mammary adenocarcinoma 13762 in female Fischer rats has been used as a model for studying postoperative adjuvant chemotherapy, using methotrexate (Mtx) and 5-fluouracil (5FU) either singly or in combinations." | 3.65 | Adjuvant postoperative chemotherapy with 5-fluorouracil and methotrexate: effect of schedule of administration on metastasis of 13762 mammary adenocarcinoma. ( Khwaja, TA; Lee, YT, 1977) |
| " Following surgical removal of spontaneous mammary adenocarcinomas, phenylalanine mustard, adriamycin, and 5-fluorouracil (PAF) were administered at 4, 2, and 50 mg/kg, respectively, once a week for six injections." | 3.65 | Comparison of adjuvant chemotherapeutic activity against primary and metastatic spontaneous murine tumors. ( Anderson, JC; Fugmann, RA; Martin, DS; Stolfi, RL, 1977) |
| "The potential impact on cancer mortality from these treatment results is obvious." | 2.36 | Multimodal primary cancer treatment (adjuvant chemotherapy): current results and future prospects. ( DeVita, VT; Weiss, RB, 1979) |
| "Nine days after CAF treatment, residual tumors showed features of regressive alterations and were composed of mesenchymal-like tumor cells, infiltrating immune cells and some tumor-associated fibroblasts with an intense deposition of collagen." | 1.42 | Chemotherapy of WAP-T mouse mammary carcinomas aggravates tumor phenotype and enhances tumor cell dissemination. ( Alves, F; Deppert, W; Jannasch, K; Lenfert, E; Maenz, C; Wegwitz, F, 2015) |
| "Multiorgan metastasis of drug-resistant 4T1 breast tumors was totally resistant to doxorubicin treatment." | 1.37 | Increased expression of P-glycoprotein is associated with doxorubicin chemoresistance in the metastatic 4T1 breast cancer model. ( Bao, L; Dash, S; Haque, A; Hazari, S; Jackson, K; Jetly, R; Moroz, K, 2011) |
| " Since clinical studies have demonstrated that bisphosphonates (BPs), specific inhibitors of osteoclastic bone resorption, are beneficial for breast cancer patients with bone metastases, we next examined the effects of UFT combined with the BP zoledronic acid (ZOL) on established bone metastases." | 1.32 | Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer. ( Hata, K; Hiraga, T; Ikeda, F; Tamura, D; Ueda, A; Williams, PJ; Yoneda, T, 2003) |
| "A total of 49 paired of breast cancer tissues and the adjacent normal breast tissues were evaluated in this study." | 1.32 | DPD activity and immunohistochemical DPD expression in human breast cancer. ( Horiguchi, J; Iijima, K; Iino, Y; Koibuchi, Y; Morishita, Y; Ninomiya, J; Takei, H; Yokoe, T; Yoshida, T, 2004) |
| "5% when combined with 5-FU (P < 0." | 1.32 | Hyperbaric oxygen alone or combined with 5-FU attenuates growth of DMBA-induced rat mammary tumors. ( Iversen, VV; Maehle, BO; Reed, RK; Straume, O; Stuhr, LE, 2004) |
| " Thus, by using a dosing schedule of cyclophosphamide that provided more sustained apoptosis of endothelial cells within the vascular bed of a tumor, we show that a chemotherapeutic agent can more effectively control tumor growth in mice, regardless of whether the tumor cells are drug resistant." | 1.31 | Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. ( Browder, T; Butterfield, CE; Folkman, J; Kräling, BM; Marshall, B; O'Reilly, MS; Shi, B, 2000) |
| "The energy metabolism of FM3A tumors in C3H mice following radiotherapy (20 Gy or 40 Gy), 5-fluorouracil compound (UFT) chemotherapy or radiotherapy (20 Gy) combined with UFT was investigated by in vivo 31P-MR spectroscopy on day 2 after treatment." | 1.29 | Changes of 31P-MR spectroscopy in experimental tumors following radiotherapy combined with 5-fluorouracil compound (UFT). ( Ohkubo, M, 1993) |
| "A dosage form comprising 5-fluorouracil (5-FU, 25 mg/ml) adsorbed on a suspension of micronized charcoal (100 mg/ml) 2-5 microns in diameter, adsorbing 5-FU in aqueous solution was studied for intratumor treatment of mammary carcinoma in animal experiments." | 1.28 | Intratumor treatment of C3H mouse mammary carcinoma with 5-fluorouracil adsorbed on activated charcoal particles. ( Amdidouche, D; Bonhomme, L; Faure, E; Fredj, G; Guisteau, D; Mathieu, MC; Naveau, S, 1992) |
| " Groups of tumor bearing mice were treated with saline, leucovorin, 5-fluorouracil or 5-fluourouracil plus leucovorin on an optimal dosage schedule." | 1.28 | Selective expansion of 5,10-methylenetetrahydrofolate pools and modulation of 5-fluorouracil antitumor activity by leucovorin in vivo. ( Dreyfuss, A; el-Magharbel, I; Frei, E; Holden, SA; Jones, SM; Rosowsky, A; Trites, D; Wright, JE, 1989) |
| " Using such low, nontherapeutic, but biochemically active doses of PALA in combination with 5-fluorouracil (FUra(, it was possible to maintain the dose of FUra at its full maximum tolerated single agent dose." | 1.27 | Therapeutic utility of utilizing low doses of N-(phosphonacetyl)-L-aspartic acid in combination with 5-fluorouracil: a murine study with clinical relevance. ( Casper, ES; Martin, DS; Sawyer, RC; Spiegelman, S; Stolfi, RL; Young, CW, 1983) |
| " Findings were as follow: 1) Administration of beta-type Interferon for 2 days, following the administration of a toxic dose (140 mg/kg/w) of 5-FU, revealed significant protection from mortality in C3H/He mice." | 1.27 | [Prevention of 5-FU induced toxicity in C3 H/HE mice with interferon or with interferon inducers (poly 1: C, OK-432, Lentinan)]. ( Abe, R; Akimoto, M; Ewasaki, H; Kasai, M; Matano, S; Nakajima, Y; Ueki, H, 1984) |
| "5-fluorouracil that was less active in the used therapeutic doses did not cause similar changes in the LSA levels." | 1.27 | [Changes in the content and composition of gangliosides of tumors as affected by chemotherapeutic agents]. ( Bassalyk, LS; Kozlov, AM; Novikov, AM; Sof'ina, ZP, 1984) |
| " Weekly administration of FUra at 85 mg/kg resulted in toxicity expressed in body weight loss and in depressed peripheral WBC levels; however, the magnitude of these toxic effects decreased significantly by the 5th week of treatment." | 1.27 | Decreased host toxicity in vivo during chronic treatment with 5-flourouracil. ( Darnowski, JW; Lau-Cam, CA; Martin, DS; Sawyer, RC; Stolfi, RL, 1985) |
| "Patients with breast cancer may show an increased requirement for thiamin particularly when treated with 5-fluorouracil, and a number of metabolic disturbances in which ascorbic acid may play a central role." | 1.26 | Nutrition and breast cancer. ( Dickerson, JW, 1979) |
| " The effect of the immunopotentiator when used in combination with alkylating agents was greater than that seen when it was used with the antimetabolite 5-fluorouracil." | 1.26 | The effect of Corynebacterium parvum in combination with 5-fluorouracil, L-phenylalanine mustard, or methotrexate on the inhibition of tumor growth. ( Fisher, B; Rubin, H; Saffer, E; Wolmark, N, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 108 (59.02) | 18.7374 |
| 1990's | 33 (18.03) | 18.2507 |
| 2000's | 20 (10.93) | 29.6817 |
| 2010's | 18 (9.84) | 24.3611 |
| 2020's | 4 (2.19) | 2.80 |
| Authors | Studies |
|---|---|
| Carrasco, E | 1 |
| Álvarez, PJ | 1 |
| Melguizo, C | 1 |
| Prados, J | 1 |
| Álvarez-Manzaneda, E | 1 |
| Chahboun, R | 1 |
| Messouri, I | 1 |
| Vázquez-Vázquez, MI | 1 |
| Aránega, A | 1 |
| Rodríguez-Serrano, F | 1 |
| Szczęch, M | 1 |
| Hinz, A | 1 |
| Łopuszyńska, N | 1 |
| Bzowska, M | 1 |
| Węglarz, WP | 1 |
| Szczepanowicz, K | 1 |
| Chen, M | 1 |
| Chen, S | 1 |
| Zhu, F | 1 |
| Wang, F | 1 |
| Tian, H | 1 |
| Fan, Z | 1 |
| Ke, S | 1 |
| Hou, Z | 1 |
| Li, Y | 1 |
| Kazakov, OV | 5 |
| Kabakov, AV | 5 |
| Poveshchenko, AF | 5 |
| Raiter, TV | 5 |
| Strunkin, DN | 5 |
| Bogachev, SS | 1 |
| Lykov, AP | 4 |
| Konenkov, VI | 5 |
| Galot-Linaldi, J | 1 |
| Hernández-Sánchez, KM | 1 |
| Estrada-Muñiz, E | 1 |
| Vega, L | 1 |
| Ishchenko, IY | 2 |
| Michurina, SV | 2 |
| Song, Y | 1 |
| Lu, M | 1 |
| Qiu, H | 1 |
| Yin, J | 1 |
| Luo, K | 1 |
| Zhang, Z | 3 |
| Jia, X | 1 |
| Zheng, G | 1 |
| Liu, H | 2 |
| He, Z | 1 |
| Yang, L | 1 |
| Song, X | 1 |
| Gong, T | 2 |
| Wang, L | 1 |
| Zhao, T | 1 |
| Li, L | 2 |
| Zhou, C | 1 |
| Sun, X | 1 |
| Poveshchenko, OV | 2 |
| Zhang, SH | 1 |
| Zhang, H | 1 |
| He, HW | 1 |
| Li, XQ | 1 |
| Zhang, YP | 1 |
| Shao, RG | 1 |
| Chauhan, VP | 1 |
| Martin, JD | 1 |
| Lacorre, DA | 1 |
| Jain, SR | 1 |
| Kozin, SV | 1 |
| Stylianopoulos, T | 1 |
| Mousa, AS | 1 |
| Han, X | 1 |
| Adstamongkonkul, P | 1 |
| Popović, Z | 1 |
| Huang, P | 1 |
| Bawendi, MG | 1 |
| Boucher, Y | 1 |
| Jain, RK | 1 |
| Fanciullino, R | 1 |
| Mollard, S | 1 |
| Correard, F | 1 |
| Giacometti, S | 1 |
| Serdjebi, C | 1 |
| Iliadis, A | 1 |
| Ciccolini, J | 1 |
| Jannasch, K | 1 |
| Wegwitz, F | 1 |
| Lenfert, E | 1 |
| Maenz, C | 1 |
| Deppert, W | 1 |
| Alves, F | 1 |
| Vanhoecke, B | 1 |
| Bateman, E | 1 |
| Mayo, B | 1 |
| Vanlancker, E | 1 |
| Stringer, A | 1 |
| Thorpe, D | 1 |
| Keefe, D | 1 |
| Bwatanglang, IB | 1 |
| Mohammad, F | 1 |
| Yusof, NA | 1 |
| Abdullah, J | 1 |
| Alitheen, NB | 1 |
| Hussein, MZ | 1 |
| Abu, N | 1 |
| Mohammed, NE | 1 |
| Nordin, N | 1 |
| Zamberi, NR | 1 |
| Yeap, SK | 1 |
| Bondarenko, NA | 1 |
| Pledgie-Tracy, A | 1 |
| Billam, M | 1 |
| Hacker, A | 1 |
| Sobolewski, MD | 1 |
| Woster, PM | 1 |
| Casero, RA | 1 |
| Davidson, NE | 1 |
| Moen, I | 1 |
| Tronstad, KJ | 1 |
| Kolmannskog, O | 1 |
| Salvesen, GS | 1 |
| Reed, RK | 3 |
| Stuhr, LE | 3 |
| Scaltriti, M | 1 |
| Chandarlapaty, S | 1 |
| Prudkin, L | 1 |
| Aura, C | 1 |
| Jimenez, J | 1 |
| Angelini, PD | 1 |
| Sánchez, G | 1 |
| Guzman, M | 1 |
| Parra, JL | 1 |
| Ellis, C | 1 |
| Gagnon, R | 1 |
| Koehler, M | 1 |
| Gomez, H | 1 |
| Geyer, C | 1 |
| Cameron, D | 1 |
| Arribas, J | 1 |
| Rosen, N | 1 |
| Baselga, J | 1 |
| Bao, L | 1 |
| Haque, A | 1 |
| Jackson, K | 1 |
| Hazari, S | 1 |
| Moroz, K | 1 |
| Jetly, R | 1 |
| Dash, S | 1 |
| Sobočanec, S | 1 |
| Balog, T | 1 |
| Šariċ, A | 1 |
| Mačak-Šafranko, Ž | 1 |
| Štroser, M | 1 |
| Žarković, K | 1 |
| Žarković, N | 1 |
| Stojković, R | 1 |
| Ivanković, S | 1 |
| Marotti, T | 1 |
| Gong, X | 1 |
| Moghaddam, MJ | 1 |
| Sagnella, SM | 1 |
| Conn, CE | 1 |
| Danon, SJ | 1 |
| Waddington, LJ | 1 |
| Drummond, CJ | 1 |
| Wu, L | 1 |
| Tannock, IF | 4 |
| Hiraga, T | 2 |
| Ueda, A | 1 |
| Tamura, D | 1 |
| Hata, K | 2 |
| Ikeda, F | 2 |
| Williams, PJ | 1 |
| Yoneda, T | 2 |
| STROUD, AN | 1 |
| MCDONALD, GO | 1 |
| SVOBODA, BR | 1 |
| BRUES, AM | 1 |
| MCALISTER, WH | 1 |
| DIPAOLO, JA | 1 |
| Horiguchi, J | 1 |
| Yoshida, T | 1 |
| Koibuchi, Y | 1 |
| Iijima, K | 1 |
| Ninomiya, J | 1 |
| Takei, H | 1 |
| Yokoe, T | 3 |
| Iino, Y | 3 |
| Morishita, Y | 2 |
| Hayward, R | 1 |
| Ruangthai, R | 1 |
| Schneider, CM | 1 |
| Hyslop, RM | 1 |
| Strange, R | 1 |
| Westerlind, KC | 1 |
| Iversen, VV | 2 |
| Straume, O | 1 |
| Maehle, BO | 1 |
| Gade, TP | 1 |
| Spees, WM | 1 |
| Le, HC | 1 |
| Zakian, KL | 1 |
| Ponomarev, V | 1 |
| Doubrovin, M | 1 |
| Gelovani, JG | 1 |
| Koutcher, JA | 4 |
| Kershaw, MH | 1 |
| Jackson, JT | 1 |
| Haynes, NM | 1 |
| Teng, MW | 1 |
| Moeller, M | 1 |
| Hayakawa, Y | 1 |
| Street, SE | 1 |
| Cameron, R | 1 |
| Tanner, JE | 1 |
| Trapani, JA | 1 |
| Smyth, MJ | 1 |
| Darcy, PK | 1 |
| Ishimori, T | 1 |
| Tatsumi, M | 1 |
| Wahl, RL | 1 |
| Kitagaki, J | 1 |
| Fujimoto-Ouchi, K | 1 |
| Tanaka, Y | 2 |
| Ahmed, M | 1 |
| Lukyanov, AN | 1 |
| Torchilin, V | 1 |
| Tournier, H | 1 |
| Schneider, AN | 1 |
| Goldberg, SN | 1 |
| Wan, L | 1 |
| Cao, D | 1 |
| Zeng, J | 1 |
| Yan, R | 1 |
| Pizzorno, G | 1 |
| Salnikov, AV | 1 |
| Salvesen, G | 1 |
| Rubin, K | 1 |
| Bijnsdorp, IV | 1 |
| Comijn, EM | 1 |
| Padron, JM | 1 |
| Gmeiner, WH | 1 |
| Peters, GJ | 1 |
| Gropper, L | 1 |
| Shimkin, MB | 1 |
| Martin, DS | 15 |
| Stolfi, RL | 13 |
| Sawyer, RC | 8 |
| Spiegelman, S | 6 |
| Casper, ES | 1 |
| Young, CW | 2 |
| Namba, M | 2 |
| Miyoshi, T | 2 |
| Kanamori, T | 1 |
| Nobuhara, M | 2 |
| Kimoto, T | 2 |
| Ogawa, S | 2 |
| Browman, GP | 1 |
| Akimoto, M | 5 |
| Ueki, H | 3 |
| Nakajima, Y | 3 |
| Matano, S | 2 |
| Ewasaki, H | 1 |
| Abe, R | 3 |
| Kasai, M | 3 |
| Maisin, H | 1 |
| Anckaert, MA | 1 |
| De Coster, B | 1 |
| Yamazaki, K | 1 |
| Ishikawa, H | 1 |
| Endo, K | 1 |
| Arai, T | 1 |
| Ogawa, T | 1 |
| Hoshino, K | 1 |
| Ishida, T | 1 |
| Takahashi, T | 2 |
| Ishiwata, K | 2 |
| Ido, T | 3 |
| Monma, M | 1 |
| Iwata, R | 1 |
| Abe, Y | 2 |
| Matsuzawa, T | 2 |
| Tsurumi, Y | 1 |
| Kameyama, M | 1 |
| Kozlov, AM | 1 |
| Novikov, AM | 1 |
| Bassalyk, LS | 1 |
| Sof'ina, ZP | 1 |
| Berger, MR | 1 |
| Habs, M | 3 |
| Schmähl, D | 6 |
| Vaage, J | 2 |
| Costanza, ME | 2 |
| Fiebig, HH | 3 |
| Vrba, M | 1 |
| Adámek, R | 1 |
| Blasko, M | 1 |
| Brezina, V | 1 |
| Chrz, R | 1 |
| Goetz, P | 1 |
| Michalová, K | 1 |
| Musilová, J | 1 |
| Novotná, B | 1 |
| Pogosianz, HE | 1 |
| Raposa, T | 1 |
| Siracký, J | 1 |
| Sokova, OI | 1 |
| Thust, R | 1 |
| Ujházy, V | 1 |
| Volgareva, GM | 1 |
| Teller, MN | 1 |
| Stock, CC | 1 |
| Bowie, M | 1 |
| Chou, TC | 1 |
| Budinger, JM | 1 |
| Kiang, DT | 1 |
| Kennedy, BJ | 1 |
| Berger, M | 1 |
| Sawyer, R | 2 |
| Nayak, R | 3 |
| Ritzi, E | 1 |
| Stolfi, R | 2 |
| Martin, D | 2 |
| Schabel, FM | 2 |
| Skipper, HE | 1 |
| Trader, MW | 1 |
| Laster, WR | 1 |
| Corbett, TH | 1 |
| Griswold, DP | 1 |
| Cowan, K | 1 |
| Lippman, M | 1 |
| Falk, RE | 1 |
| Hardy, M | 1 |
| Makowka, L | 1 |
| Teodorczyk-Injeyan, J | 1 |
| Falk, JA | 1 |
| Tokuzen, R | 1 |
| Iigo, M | 3 |
| Hoshi, A | 2 |
| Kuretani, K | 1 |
| Lin, PZ | 1 |
| Ferguson, T | 1 |
| Ritzi, EM | 3 |
| Pyo, S | 1 |
| Eliason, JF | 1 |
| Inoue, T | 1 |
| Kubota, A | 1 |
| Horii, I | 1 |
| Hartmann, D | 1 |
| Ohkubo, M | 1 |
| Rockwell, S | 1 |
| Sakamoto, S | 1 |
| Mizuno, M | 1 |
| Kudo, H | 1 |
| Suzuki, S | 1 |
| Kasahara, N | 1 |
| Sugiura, Y | 1 |
| Mori, T | 2 |
| Nagasawa, H | 1 |
| Taguchi, T | 1 |
| Ashizawa, T | 1 |
| Ishida, H | 1 |
| Okabe, M | 1 |
| Gomi, K | 1 |
| McElhinney, RS | 4 |
| McCormick, JE | 4 |
| Bibby, MC | 4 |
| Double, JA | 4 |
| Radacic, M | 4 |
| Dumont, P | 4 |
| Fox, ME | 1 |
| Lemmon, MJ | 1 |
| Mauchline, ML | 1 |
| Davis, TO | 1 |
| Giaccia, AJ | 1 |
| Minton, NP | 1 |
| Brown, JM | 1 |
| Mester, J | 1 |
| DeGoeij, K | 1 |
| Sluyser, M | 1 |
| Raghunathan, K | 1 |
| Schmitz, JC | 1 |
| Priest, DG | 1 |
| Street, JC | 1 |
| Alfieri, AA | 1 |
| Traganos, F | 1 |
| Branda, RF | 1 |
| Nigels, E | 1 |
| Lafayette, AR | 1 |
| Hacker, M | 1 |
| Lemaire, L | 1 |
| Howe, FA | 1 |
| Rodrigues, LM | 1 |
| Griffiths, JR | 1 |
| Endo, M | 1 |
| Shinbori, N | 1 |
| Fukase, Y | 1 |
| Sawada, N | 1 |
| Ishikawa, T | 1 |
| Ishitsuka, H | 1 |
| Ehrnrooth, E | 1 |
| von der Maase, H | 2 |
| Sørensen, BS | 1 |
| Poulsen, JH | 1 |
| Horsman, MR | 1 |
| Liu, R | 1 |
| Page, C | 1 |
| Beidler, DR | 1 |
| Wicha, MS | 1 |
| Núñez, G | 1 |
| Tunggal, JK | 1 |
| Melo, T | 1 |
| Ballinger, JR | 1 |
| Kang, CD | 1 |
| Ahn, BK | 1 |
| Jeong, CS | 1 |
| Kim, KW | 1 |
| Lee, HJ | 1 |
| Yoo, SD | 1 |
| Chung, BS | 1 |
| Kim, SH | 1 |
| Browder, T | 1 |
| Butterfield, CE | 1 |
| Kräling, BM | 1 |
| Shi, B | 1 |
| Marshall, B | 1 |
| O'Reilly, MS | 1 |
| Folkman, J | 1 |
| Yamashita, A | 1 |
| Maruo, K | 1 |
| Suzuki, K | 1 |
| Shirota, K | 1 |
| Kobayashi, K | 1 |
| Hioki, K | 1 |
| Papadopoulou, MV | 1 |
| Ji, M | 1 |
| Bloomer, WD | 1 |
| Takeda, Y | 1 |
| Yoshizaki, I | 1 |
| Nonaka, Y | 1 |
| Yanagie, H | 1 |
| Matsuzawa, A | 1 |
| Eriguchi, M | 1 |
| Zhu, Y | 1 |
| Hao, X | 1 |
| Sun, H | 1 |
| Shani, J | 2 |
| Wolf, W | 2 |
| Schlesinger, T | 1 |
| Atkins, HL | 1 |
| Bradley-Moore, PR | 1 |
| Casella, V | 1 |
| Fowler, JS | 1 |
| Greenberg, D | 1 |
| Lambrecht, RM | 1 |
| MacGregor, R | 1 |
| Mantescu, C | 1 |
| Neirinckx, R | 1 |
| Som, P | 1 |
| Wolf, AP | 1 |
| Wodinsky, I | 1 |
| Meaney, K | 1 |
| Shoemaker, JP | 2 |
| Dagher, RK | 1 |
| Heppner, GH | 4 |
| Calabresi, P | 3 |
| Fisher, B | 2 |
| Pallavicini, MG | 1 |
| Cohen, AM | 1 |
| Dethlefsen, LA | 1 |
| Gray, JW | 1 |
| Weiss, RB | 1 |
| DeVita, VT | 1 |
| Dickerson, JW | 1 |
| Lee, YT | 2 |
| Görlich, M | 1 |
| Heise, E | 1 |
| Számel, I | 1 |
| Kerpel-Fronius, S | 1 |
| de Ruiter, J | 1 |
| Cramer, SJ | 1 |
| van Putten, LM | 1 |
| Khwaja, TA | 1 |
| Tseng, WC | 1 |
| Medina, D | 2 |
| Randerath, K | 1 |
| Baba, T | 1 |
| Kidera, Y | 1 |
| Kimura, NT | 1 |
| Aoki, K | 1 |
| Kamura, T | 1 |
| Taniguchi, S | 1 |
| Nishikawa, K | 1 |
| Dexter, DL | 1 |
| DeNucci, T | 1 |
| Miller, FR | 2 |
| Braunschweiger, PG | 1 |
| Stragand, JJ | 1 |
| Schiffer, LM | 1 |
| Brown, I | 1 |
| Ward, HW | 1 |
| de Loecker, W | 1 |
| van der Schueren, G | 1 |
| Cohen, D | 2 |
| Yron, I | 2 |
| Grover, NB | 1 |
| Weiss, DW | 2 |
| Steiger, E | 1 |
| Oram-Smith, J | 1 |
| Miller, E | 1 |
| Kuo, L | 1 |
| Vars, HM | 1 |
| Fugmann, RA | 1 |
| Anderson, JC | 1 |
| Shepherd, F | 1 |
| Rubin, H | 1 |
| Saffer, E | 1 |
| Wolmark, N | 1 |
| Popovic, P | 1 |
| Popovic, V | 1 |
| Weathers, D | 1 |
| Nord, LD | 3 |
| Colofiore, JR | 1 |
| Lee, MY | 1 |
| Lottsfeldt, JL | 1 |
| Fevold, KL | 1 |
| Yoshida, M | 1 |
| Sugamata, N | 1 |
| Maemura, M | 1 |
| Ohwada, S | 1 |
| Ishikita, T | 1 |
| Horiuchi, R | 1 |
| Bonhomme, L | 1 |
| Mathieu, MC | 1 |
| Amdidouche, D | 1 |
| Faure, E | 1 |
| Guisteau, D | 1 |
| Fredj, G | 1 |
| Naveau, S | 1 |
| Nielsen, LL | 1 |
| Gurnani, M | 1 |
| Tyler, RD | 1 |
| Grau, C | 1 |
| Overgaard, J | 1 |
| Sakata, K | 1 |
| Kwok, TT | 1 |
| Murphy, BJ | 1 |
| Laderoute, KR | 1 |
| Gordon, GR | 1 |
| Sutherland, RM | 1 |
| Kornblith, AB | 1 |
| Devitt, ML | 1 |
| Cowburn, D | 1 |
| Morimoto, T | 2 |
| Yamamoto, H | 2 |
| Komaki, K | 1 |
| Konishi, N | 1 |
| Tanaka, T | 1 |
| Yamakawa, T | 1 |
| Sasa, M | 1 |
| Monden, Y | 1 |
| Nishikata, K | 1 |
| Szinai, I | 1 |
| Veres, Z | 1 |
| Szabolcs, A | 1 |
| De Clercq, E | 1 |
| Torosian, MH | 1 |
| Jalali, S | 1 |
| Nguyen, HQ | 1 |
| Shirasaka, T | 1 |
| Fukushima, M | 1 |
| Shimamoto, Y | 1 |
| Kimura, Y | 1 |
| Ohshimo, H | 1 |
| Imaoka, T | 1 |
| Kimura, A | 1 |
| Utsunomiya, T | 1 |
| Fujii, S | 1 |
| Boothman, DA | 1 |
| Briggle, TV | 1 |
| Greer, S | 1 |
| Ohuchi, N | 1 |
| Hirakawa, H | 1 |
| Abe, M | 1 |
| Nishihira, T | 2 |
| Mori, S | 1 |
| Monden, A | 1 |
| Rak, J | 1 |
| Kuśnierczyk, H | 1 |
| Strzadała, L | 1 |
| Kłosiewicz, S | 1 |
| Radzikowski, C | 1 |
| Atassi, G | 3 |
| Pratesi, G | 3 |
| Fukushima, K | 1 |
| Wright, JE | 1 |
| Dreyfuss, A | 1 |
| el-Magharbel, I | 1 |
| Trites, D | 1 |
| Jones, SM | 1 |
| Holden, SA | 1 |
| Rosowsky, A | 1 |
| Frei, E | 1 |
| Yoshioka, A | 1 |
| Tanaka, S | 1 |
| Hiraoka, O | 1 |
| Koyama, Y | 1 |
| Hirota, Y | 1 |
| Wataya, Y | 1 |
| Komatsumoto, M | 1 |
| Li, S | 1 |
| Hamada, J | 1 |
| Takeichi, N | 1 |
| Hosokawa, M | 1 |
| Okayasu, T | 1 |
| Tanabe, T | 1 |
| Kobayashi, H | 1 |
| Monge, OR | 1 |
| Rofstad, EK | 1 |
| Kaalhus, O | 1 |
| Murakami, M | 1 |
| Baumgart, J | 1 |
| Zhukovskaya, NV | 1 |
| Anisimov, VN | 1 |
| Sinha, DK | 1 |
| White, CJ | 1 |
| Eibl-Eibesfeldt, B | 1 |
| Storz, V | 1 |
| Kummermehr, J | 1 |
| Schalhorn, A | 1 |
| Sawano, A | 1 |
| Kimura, M | 1 |
| Kitamura, M | 1 |
| Tominaga, T | 1 |
| Hayashi, K | 1 |
| Takahashi, I | 1 |
| Kosaki, G | 1 |
| Akazawa, S | 1 |
| Kumai, R | 1 |
| Shimizu, K | 1 |
| Ayusawa, D | 1 |
| Seno, T | 1 |
| Yoshida, S | 1 |
| Darnowski, JW | 1 |
| Lau-Cam, CA | 1 |
| Manaka, RC | 1 |
| Young, D | 1 |
| Cohen, JL | 1 |
| Miller, BE | 1 |
| Hasegawa, R | 1 |
| Hahn, GM | 2 |
| Ray, GR | 1 |
| Gordon, LF | 2 |
| Kallman, RF | 1 |
| Kurkjian, SD | 1 |
| Robinson, E | 1 |
| Adelberg, MG | 1 |
| Mekori, T | 1 |
| Haber, M | 1 |
| Hecker, D | 1 |
| Klug, H | 1 |
| Tanneberger, S | 1 |
| Rose, H | 1 |
| Czerniak, P | 1 |
| Eylan, E | 1 |
| Frenkel, O | 1 |
| Sinkover, A | 1 |
| Bernard, LJ | 1 |
| Allen, M | 1 |
| Birchette, C | 1 |
| Royal, J | 1 |
| Walker, M | 1 |
| Griswold, DE | 1 |
| Di Lorenzo, J | 1 |
| Poplin, EA | 1 |
| Rees, ED | 1 |
| Ross, A | 1 |
| Edwards, AJ | 1 |
| Rowland, GF | 1 |
| Vasnetsova, SS | 1 |
| Bulkina, ZP | 1 |
| Turkevich, NM | 1 |
| Suhrland, LG | 1 |
| Benson, J | 1 |
| Labelle, E | 1 |
| Kubo, K | 1 |
| Tamura, J | 1 |
| Usami, H | 1 |
| Funahashi, F | 1 |
| Ninomiya, E | 1 |
| Tugarinov, OA | 1 |
| Smolianskaia, AZ | 1 |
| Konovalova, AL | 1 |
| Grant, JP | 1 |
| Harper PV FERGUSON, DJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Changes in Tumor Vascularity Depicted by Contrast-Enhanced Endoscopic Ultrasonography as a Predictor of Treatment Efficacy in Patients With Locally Advanced and Metastatic Pancreatic Cancer (PEACE)[NCT03513198] | 200 participants (Anticipated) | Observational | 2018-05-01 | Not yet recruiting | |||
| A Phase I Pilot Trial to Study the Safety and Efficacy of Concomitant Radiotherapy and Zoledronic Acid for the Palliation of Bone Metastases From Breast Cancer, Prostate Cancer and Lung Cancer[NCT00264420] | Phase 1 | 4 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| Phase II Study of an All-Oral Combination of Capecitabine (X) and Cyclophosphamide (C) in Patients With Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer[NCT00589901] | Phase 2 | 60 participants (Anticipated) | Interventional | 2006-08-31 | Recruiting | ||
| A Phase 2 Clinical Trial:Low -Dose-bevacizumab and Pemetrexed Versus Treatment of Physician's Choice in Metastatic HER2-negative Breast Cancer Patients After Failure of Taxanes and Anthracycline-containing Regimens[NCT02829008] | Phase 2 | 120 participants (Anticipated) | Interventional | 2016-04-30 | Active, not recruiting | ||
| Multicentre Randomized Phase II Study of Neoadjuvant Trastuzumab Plus Docetaxel With and Without Bevacizumab and Trastuzumab Plus Docetaxel Plus Non-pegylated Liposome-encapsulated Doxorubicin (NPLD) With and Without Bevacizumab in HER2-positive Early Bre[NCT01367028] | Phase 2 | 100 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for fluorouracil and Experimental Mammary Neoplasms
| Article | Year |
|---|---|
Dark Agouti rat model of chemotherapy-induced mucositis: establishment and current state of the art.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluor | 2015 |
Endocrine and cytostatic treatment of experimental mammary cancer.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Agents; Carmustine; Castration; Cyclophosp | 1980 |
Recent progress in breast cancer management. Combined modality (adjuvant) therapy.
Topics: Adult; Animals; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; | 1981 |
[Development of fluorinated pyrimidines in Japan].
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Fluorode | 1993 |
Rationale for adjuvant chemotherapy.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carmustine; Cyclophosphamide; Cytarabine; Doxorubi | 1977 |
Multimodal primary cancer treatment (adjuvant chemotherapy): current results and future prospects.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Colonic Neoplasms; Evaluation Stud | 1979 |
6 trials available for fluorouracil and Experimental Mammary Neoplasms
| Article | Year |
|---|---|
Clinical application of the concept of methotrexate plus 5-FU sequence-dependent "synergy": how good is the evidence?
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; DNA; Drug Synergi | 1984 |
Chemoendocrine therapy in advanced breast cancer.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide | 1981 |
Recent progress in breast cancer management. Combined modality (adjuvant) therapy.
Topics: Adult; Animals; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; | 1981 |
Adjuvant chemotherapy in the primary management of breast cancer.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Division; Cell Survival; Clinica | 1977 |
[Modulation of the anti-tumor effect of BRM under various nutritional or endocrine conditions].
Topics: Animals; Combined Modality Therapy; Endocrine Glands; Female; Fluorouracil; Humans; Lentinan; Mammar | 1986 |
[The tumor activity test].
Topics: Animals; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Diethylstilbestrol; Drug Syne | 1972 |
172 other studies available for fluorouracil and Experimental Mammary Neoplasms
| Article | Year |
|---|---|
Novel merosesquiterpene exerts a potent antitumor activity against breast cancer cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Proliferation; Cell Su | 2014 |
Polyaminoacid Based Core@shell Nanocarriers of 5-Fluorouracil: Synthesis, Properties and Theranostics Application.
Topics: Amino Acids; Animals; Antimetabolites, Antineoplastic; Drug Carriers; Female; Fluorouracil; Mammary | 2021 |
"Watson-Crick G[triple bond, length as m-dash]C"-inspired supramolecular nanodrug of methotrexate and 5-fluorouracil for tumor microenvironment-activatable self-recognizing synergistic chemotherapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytosine; Drug | 2020 |
Morphological Study of Mesenteric Lymph Nodes in Rats with Experimental Breast Cancer Treated with Fragmented Double-Stranded DNA.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide | 2020 |
Anacardic Acids from
Topics: Anacardiaceae; Anacardic Acids; Animals; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Carbop | 2021 |
Anterior Mediastinal Lymph Nodes in Chemically Induced Breast Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinogens; Cell Proliferation; Cyclophosp | 2017 |
Activation of FOXO3a reverses 5-Fluorouracil resistance in human breast cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cyclin-Dependen | 2018 |
Enhanced anti-tumor and anti-metastasis efficacy against breast cancer with an intratumoral injectable phospholipids-based phase separation gel co-loaded with 5-fluotouracil and magnesium oxide by neutralizing acidic microenvironment.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Female; Fluo | 2018 |
Effect of Neoadjuvant and Adjuvant Therapy of Experimental Breast Cancer on the Structure of Mesenteric Lymph Nodes.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Fluorouracil; Lym | 2018 |
Lidamycin up-regulates the expression of thymidine phosphorylase and enhances the effects of capecitabine on the growth and pulmonary metastases of murine breast carcinoma.
Topics: Aminoglycosides; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Capecit | 2013 |
Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensins; Animals; Antineoplastic Agents; Cell Hypoxia; | 2013 |
Biodistribution, tumor uptake and efficacy of 5-FU-loaded liposomes: why size matters.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Drug Compounding; Dr | 2014 |
Chemotherapy of WAP-T mouse mammary carcinomas aggravates tumor phenotype and enhances tumor cell dissemination.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cyclo | 2015 |
In vivo tumor targeting and anti-tumor effects of 5-fluororacil loaded, folic acid targeted quantum dot system.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cell Survival; Cells, Cultured; Dose-Response Re | 2016 |
Levels of miRNA and Hormones in Thoracic Duct Lymph in Rats with Experimental Breast Cancer Induced by N-Methyl-N-Nitrosourea.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinogens; Cyclophosphamide; Estradiol; F | 2017 |
The Thymus in Experimental Mammary Carcinogenesis and Polychemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinogenesis; Carcinogens; Cell Transform | 2017 |
The role of the polyamine catabolic enzymes SSAT and SMO in the synergistic effects of standard chemotherapeutic agents with a polyamine analogue in human breast cancer cell lines.
Topics: Acetyltransferases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2010 |
Hyperoxia increases the uptake of 5-fluorouracil in mammary tumors independently of changes in interstitial fluid pressure and tumor stroma.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Blood Volume; Dose-Response Relationship, | 2009 |
Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor.
Topics: 3T3 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; | 2010 |
Increased expression of P-glycoprotein is associated with doxorubicin chemoresistance in the metastatic 4T1 breast cancer model.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Line, T | 2011 |
Antitumor effect of Croatian propolis as a consequence of diverse sex-related dihydropyrimidine dehydrogenase (DPD) protein expression.
Topics: Animals; Antineoplastic Agents; Chromatography, High Pressure Liquid; Dihydrouracil Dehydrogenase (N | 2011 |
Lamellar crystalline self-assembly behaviour and solid lipid nanoparticles of a palmityl prodrug analogue of Capecitabine--a chemotherapy agent.
Topics: Animals; Calorimetry, Differential Scanning; Capecitabine; Cell Line; Cell Line, Tumor; Cell Prolife | 2011 |
Repopulation in murine breast tumors during and after sequential treatments with cyclophosphamide and 5-fluorouracil.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cell Survival; Cyclophospham | 2003 |
Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Bo | 2003 |
UTILIZATION OF DNA AND RNA PRECURSORS AS INDICATORS OF DRUG EFFECT ON CANCER CELLS. ANL-6723.
Topics: Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Dactinomycin; DNA; DNA, Neoplasm; Fluorour | 1963 |
COMPARISON OF THE EFFECTS OF CHEMOTHERAPY AND LOCAL IRRADIATION ON THE VASCULARITY OF A TRANSPLANTED MOUSE MAMMARY ADENOCARCINOMA AND A PLEOMORPHIC SARCOMA.
Topics: Adenocarcinoma; Angiography; Animals; Blood Vessels; Fluorouracil; Mammary Neoplasms, Animal; Mammar | 1965 |
IN VITRO TEST SYSTEMS FOR CANCER CHEMOTHERAPY. 3. PRELIMINARY STUDIES OF SPONTANEOUS MAMMARY TUMORS IN MICE.
Topics: Alkylating Agents; Animals; Carcinoma, Ehrlich Tumor; Dactinomycin; Fluorouracil; Hydrocortisone; In | 1965 |
DPD activity and immunohistochemical DPD expression in human breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Lin | 2004 |
Training enhances vascular relaxation after chemotherapy-induced vasoconstriction.
Topics: Animals; Antimetabolites, Antineoplastic; Endothelium, Vascular; Female; Fluorouracil; Mammary Neopl | 2004 |
Hyperbaric oxygen alone or combined with 5-FU attenuates growth of DMBA-induced rat mammary tumors.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antimetabolites, Antineoplastic; Cell Division; Drug Comb | 2004 |
In vivo 5-fluorouracil and fluoronucleotide T1 relaxation time measurements using the variable nutation angle method.
Topics: Animals; Female; Fluorouracil; Linear Models; Magnetic Resonance Spectroscopy; Male; Mammary Neoplas | 2004 |
Gene-engineered T cells as a superior adjuvant therapy for metastatic cancer.
Topics: Animals; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2004 |
Tumor response assessment is more robust with sequential CT scanning than external caliper measurements.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Fluo | 2005 |
Preferential inhibition of bone metastases by 5'-deoxy-5-fluorouridine and capecitabine in the 4T1/luc mouse breast cancer model.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Capec | 2005 |
Combined radiofrequency ablation and adjuvant liposomal chemotherapy: effect of chemotherapeutic agent, nanoparticle size, and circulation time.
Topics: Adenocarcinoma; Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplasti | 2005 |
Modulation of uridine phosphorylase gene expression by tumor necrosis factor-alpha enhances the antiproliferative activity of the capecitabine intermediate 5'-deoxy-5-fluorouridine in breast cancer cells.
Topics: Animals; Base Sequence; Capecitabine; Deoxycytidine; DNA Primers; Drug Synergism; Electrophoretic Mo | 2006 |
High-dose, short-term, anti-inflammatory treatment with dexamethasone reduces growth and augments the effects of 5-fluorouracil on dimethyl-alpha-benzanthracene-induced mammary tumors in rats.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Anti-Inflammatory Agents; Carcinogens; Dexamethasone; Dru | 2006 |
Mechanisms of action of FdUMP[10]: metabolite activation and thymidylate synthase inhibition.
Topics: Animals; Antineoplastic Agents; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Fluorodeoxyurid | 2007 |
Combination therapy of 3-methylcholanthrene-induced mammary carcinoma in rats: effect of chemotherapy, ovariectomy, and food restriction.
Topics: Animals; Estradiol; Fluorouracil; Lucanthone; Mammary Neoplasms, Experimental; Methylcholanthrene; M | 1967 |
Therapeutic utility of utilizing low doses of N-(phosphonacetyl)-L-aspartic acid in combination with 5-fluorouracil: a murine study with clinical relevance.
Topics: Animals; Aspartic Acid; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergi | 1983 |
Combined effects of 5-fluorouracil and interferon on proliferation of human neoplastic cells in culture.
Topics: Animals; Cell Line; Cell Transformation, Neoplastic; Drug Evaluation, Preclinical; Fibroblasts; Fluo | 1982 |
Potentiation of cytotoxic effects of 5-fluorouracil by inosiplex on cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cell Survival; Drug Evaluati | 1984 |
[Prevention of 5-FU induced toxicity in C3 H/HE mice with interferon or with interferon inducers (poly 1: C, OK-432, Lentinan)].
Topics: Animals; Cell Division; Cell Line; Female; Fluorouracil; Interferon Inducers; Interferons; Lentinan; | 1984 |
[Differential effect of fractionated irradiation and the administration of 5-fluorouracil on a mammary tumor in the BALB/c/Cnb mouse].
Topics: Animals; Female; Fluorouracil; Mammary Neoplasms, Experimental; Methods; Mice; Mice, Inbred BALB C; | 1983 |
[Changes of hormone receptor status in various treatment for human breast cancer and DMBA tumor of the rat].
Topics: 9,10-Dimethyl-1,2-benzanthracene; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protoco | 1984 |
Syntheses of 18F-labeled pyrimidines and their usefulness for tumor imaging.
Topics: Animals; Chromatography, High Pressure Liquid; Floxuridine; Fluorine; Fluorouracil; Glioma; Liver Ne | 1984 |
[Changes in the content and composition of gangliosides of tumors as affected by chemotherapeutic agents].
Topics: Adenocarcinoma; Animals; Cyclophosphamide; Female; Fluorouracil; Gangliosides; Lung Neoplasms; Mamma | 1984 |
[Experimental toxicologic and therapeutic studies on the activity of the CMF(cyclophosphamide-methotrexate-5-fluorouracil) scheme versus the VMF(vincristine-methotrexate-5-fluorouracil) scheme].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma 256, Walker; Cyclophosphamide; Fe | 1984 |
Effects on metastases of drug therapy during developing and established tumor immunity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Fluorouracil; Imm | 1983 |
Incorporation of 5-fluorouracil into murine bone marrow DNA in vivo.
Topics: Animals; Bone Marrow; DNA; Female; Fluorouracil; Intestinal Mucosa; Mammary Neoplasms, Experimental; | 1984 |
Clastogenicity and sister chromatid exchange induction by ftorafur.
Topics: Animals; Burkitt Lymphoma; Cell Line; Chromosomes; Chromosomes, Human; Cricetinae; Crossing Over, Ge | 1981 |
Therapy of 7,12-dimethylbenz(a)anthracene-induced rat mammary carcinomas with combinations of 5-fluorouracil and 2 alpha-methyldihydrotestosterone propionate.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Androstanols; Animals; Dose-Response Relationship, Drug; Drug Eval | 1982 |
[Effects of protein calorie intake on immuno- and chemotherapy].
Topics: Animals; Dietary Proteins; Female; Fluorouracil; Killer Cells, Natural; Lentinan; Mammary Neoplasms, | 1982 |
Noncarcinogenic chemotherapy with a combination of vincristine, methotrexate and 5-fluorouracil (VMF) in rats.
Topics: Animals; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Ther | 1983 |
Improving the anti-tumor activity of 5-fluorouracil by increasing its incorporation into RNA via metabolic modulation.
Topics: Animals; DNA, Neoplasm; Drug Synergism; Female; Fluorouracil; Glycoproteins; Mammary Neoplasms, Expe | 1980 |
Concepts for controlling drug-resistant tumor cells.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Body Burden; Cisplatin; Cyclophosphamide; Dactinomyc | 1980 |
Sensitization to low dose 5-fluorouracil. Subsequent enhancement of its systemic antitumor effect in the rat.
Topics: Animals; Female; Fluorouracil; Male; Mammary Neoplasms, Experimental; Methotrexate; Neoplasm Metasta | 1982 |
Effect of 1-hexylcarbamoyl-5-fluorouracil on spontaneous mammary adenocarcinoma of mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Drug Administration Schedule; Female; Fluorouracil; | 1980 |
Carcinogenic activity in rats of combined treatment with cyclophosphamide, methotrexate and 5-fluorouracil.
Topics: Adrenal Gland Neoplasms; Animals; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Therapy, | 1981 |
Potentiation of the anti-tumor activity of 5FU by thymidine and its correlation with the formation of (5FU)RNA.
Topics: Animals; Colonic Neoplasms; DNA, Neoplasm; Drug Synergism; Drug Therapy, Combination; Fluorouracil; | 1980 |
Protection by testosterone from fluorouracil-induced toxicity without loss of anticancer acitvity against autochthonous murine breast tumors.
Topics: Animals; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; | 1980 |
Prevention and delay of spontaneous mammary and pituitary tumors by long- and short-term ingestion of 5-fluorouracil in Wistar-Furth rats.
Topics: Age Factors; Animals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluoro | 1980 |
In vivo interaction of anti-cancer drugs with misonidazole or metronidazole: methotrexate, 5-fluorouracil and adriamycin.
Topics: Animals; Body Weight; Doxorubicin; Drug Therapy, Combination; Fibrosarcoma; Fluorouracil; Leukocyte | 1980 |
Levels of viral glycoprotein reflect enhanced effectiveness of combined drug treatments.
Topics: Adenocarcinoma; Animals; Antigens, Viral, Tumor; Antineoplastic Combined Chemotherapy Protocols; Cel | 1994 |
The anti-tumor arotinoid Ro 40-8757 protects bone marrow from the toxic effects of 5-fluorouracil.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Female; | 1994 |
Changes of 31P-MR spectroscopy in experimental tumors following radiotherapy combined with 5-fluorouracil compound (UFT).
Topics: Adenocarcinoma; Animals; Cell Division; Combined Modality Therapy; Flow Cytometry; Fluorouracil; Mag | 1993 |
Combination therapy with radiation, mitomycin C, and 5-fluorouracil in EMT6 tumors.
Topics: Animals; Cell Survival; Combined Modality Therapy; Fluorouracil; In Vitro Techniques; Mammary Neopla | 1994 |
Suppression of mammary tumors by oral administration of 1-(2-tetrahydrofuryl)-5-fluorouracil in combination with uracil in SHN virgin mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Female; Fluorouracil; Mammary | 1993 |
[Effect of medroxyprogesterone acetate on antitumor efficacies and side effect of 5-fluorouracil].
Topics: Animals; Body Weight; Bone Marrow; Drug Synergism; Female; Fluorouracil; Lethal Dose 50; Male; Mamma | 1993 |
Nucleoside analogs. 14. The synthesis of antitumor activity in mice of molecular combinations of 5-fluorouracil and N-(2-Chloroethyl)-N-nitrosourea moieties separated by a three-carbon chain.
Topics: Animals; Antineoplastic Agents; Colonic Neoplasms; Ethylnitrosourea; Fluorouracil; Mammary Neoplasms | 1996 |
Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia.
Topics: Animals; Antimetabolites, Antineoplastic; Base Sequence; Carcinoma; Cell Survival; Cloning, Molecula | 1996 |
Modulation of [5-125I]iododeoxyuridine incorporation into tumour and normal tissue DNA by methotrexate and thymidylate synthase inhibitors.
Topics: Animals; Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NAD+); DNA, Neoplasm; Female; | 1996 |
Impact of schedule on leucovorin potentiation of fluorouracil antitumor activity in dietary folic acid deplete mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Diet; Drug Synergism; Fluor | 1997 |
In vivo and ex vivo study of metabolic and cellular effects of 5-fluorouracil chemotherapy in a mouse mammary carcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Cycle; Ethanolamines; Fluorouracil; Magnetic Re | 1997 |
Nutritional folate status influences the efficacy and toxicity of chemotherapy in rats.
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkyla | 1998 |
Assessment of induced rat mammary tumour response to chemotherapy using the apparent diffusion coefficient of tissue water as determined by diffusion-weighted 1H-NMR spectroscopy in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinogens; Diffusion; Evaluation Studies as Topic; Femal | 1999 |
Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5'-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 1999 |
The ability of hypoxia to modify the gene expression of thymidylate synthase in tumour cells in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Base Sequence; DNA Primers; Drug Resistance; Female; Fluor | 1999 |
Overexpression of Bcl-x(L) promotes chemotherapy resistance of mammary tumors in a syngeneic mouse model.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; bcl-X Protein; Drug Resistance, | 1999 |
The influence of expression of P-glycoprotein on the penetration of anticancer drugs through multicellular layers.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neop | 2000 |
Downregulation of JNK/SAPK activity is associated with the cross-resistance to P-glycoprotein-unrelated drugs in multidrug-resistant FM3A/M cells overexpressing P-glycoprotein.
Topics: Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; | 2000 |
Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cornea; Cyclophosphamide; Drug Administration Schedule; D | 2000 |
Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cornea; Cyclophosphamide; Drug Administration Schedule; D | 2000 |
Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cornea; Cyclophosphamide; Drug Administration Schedule; D | 2000 |
Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cornea; Cyclophosphamide; Drug Administration Schedule; D | 2000 |
Experimental chemotherapy against canine mammary cancer xenograft in SCID mice and its prediction of clinical effect.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2001 |
Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and tirapazamine against EMT6 tumors in mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubicin; D | 2001 |
Docetaxel alone or orally combined with 5-fluorouracil and its derivatives: effects on mouse mammary tumor cell line MM2 in vitro and in vivo.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Docetaxel; | 2001 |
[Effect of beta-carotene on mouse transplantable mammary cancer MA737].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; beta Carotene; Cisplatin; Female; Fluoroura | 1999 |
Distribution of 18F-5-fluorouracil in tumor-bearing mice and rats.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Fluo | 1978 |
Remissions of mammary adenocarcinoma in hypothyroid mice given 5-fluorouracil and chloroquine phosphate.
Topics: Adenocarcinoma; Animals; Chloroquine; Drug Therapy, Combination; Female; Fluorouracil; Hypothyroidis | 1979 |
Effect of sequence of administration of methotrexate, leucovorin, and 5-fluorouracil on mammary tumor growth and survival in syngeneic C3H mice.
Topics: Animals; Antibody Formation; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoro | 1977 |
In vivo effects of 5-fluorouracil and ftorafur[1-(tetrahydrofuran-2-yl)-5-fluorouracil] on murine mammary tumors and small intestine.
Topics: Animals; Body Weight; Cell Division; DNA; Female; Fluorouracil; Intestine, Small; Male; Mammary Neop | 1979 |
[Synergistic therapeutic effect of adriamycin with 5-fluor-uracil, with prednisolon and with cyclophosphamide on chemically induced mammary cancer of the rat (author's transl)].
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Agents; Carmustine; Cyclophosphamide; Doxo | 1977 |
The effect of ovariectomy, tamoxifen and the combination adriamycin and 5-FU on 7,12-dimethylbenz(a)anthracene induced mammary cancer of the rat.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Benz(a)Anthracenes; Castration; Doxorubicin; Drug Therapy | 1977 |
Nutrition and breast cancer.
Topics: Animals; Ascorbic Acid; Bone Neoplasms; Breast Neoplasms; Calcium; Dietary Fats; Feeding Behavior; F | 1979 |
Effect of preoperative intralesional BCG and postoperative 5-FU chemotherapy in three adenocarcinoma lines in rats.
Topics: Adenocarcinoma; Animals; BCG Vaccine; Colonic Neoplasms; Female; Fluorouracil; Male; Mammary Neoplas | 1979 |
Chemotherapeutic agents and estradiol receptor binding capacity.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Dianhydrogalactitol; Estradiol; Female; | 1979 |
Effects of combination drug therapy on the subcutaneous and pulmonary growth of a slow and a fast-growing C3H/He mammary carcinoma.
Topics: Animals; Antineoplastic Agents; Cyclophosphamide; Doxorubicin; Drug Resistance; Drug Therapy, Combin | 1979 |
Effects of local tumor treatment with surgery or irradiation followed by adjuvant chemotherapy in mice--I. Survival of bone marrow stem cells.
Topics: Animals; Antineoplastic Agents; Cell Survival; Cyclophosphamide; Drug Therapy, Combination; Female; | 1979 |
Adjuvant postoperative chemotherapy with 5-fluorouracil and methotrexate: effect of schedule of administration on metastasis of 13762 mammary adenocarcinoma.
Topics: Adenocarcinoma; Animals; BCG Vaccine; Drug Administration Schedule; Drug Therapy, Combination; Femal | 1977 |
Specific inhibition of transfer RNA methylation and modification in tissues of mice treated with 5-fluorouracil.
Topics: Animals; Female; Fluorouracil; In Vitro Techniques; Liver; Mammary Glands, Animal; Mammary Neoplasms | 1978 |
Fifty-five percent complete remission of mammary carcinoma in mice with 5-fluorouracil and chloroquine.
Topics: Animals; Chloroquine; Drug Therapy, Combination; Female; Fluorouracil; Mammary Neoplasms, Experiment | 1978 |
5-Fluorouracil O-beta-D-glucuronide as a newly synthesized chemically modified, nontoxic anticancer drug.
Topics: Animals; Female; Fluorouracil; Glucose; Glucuronates; Mammary Neoplasms, Experimental; Mice; Pyrimid | 1978 |
Heterogeneity in drug sensitivity among tumor cell subpopulations of a single mammary tumor.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line; Cyclophosphamide; Drug Resistance; Fluoro | 1978 |
Effect of methylprednisolone on cell proliferation in C3H/HeJ spontaneous mammary tumors.
Topics: Animals; Cell Cycle; Cell Division; Drug Therapy, Combination; Female; Fluorouracil; Kinetics; Mamma | 1978 |
Therapeutic consequences of antitumour drug interactions: methotrexate and 5-fluorouracil in the chemotherapy of C3H mice with transplanted mammary adenocarcinoma.
Topics: Adenocarcinoma; Animals; Drug Interactions; Drug Therapy, Combination; Female; Fluorouracil; Mammary | 1978 |
In vitro effects of methotrexate, 5-fluorouracil, cyclophosphamide and vincristine sulphate on the metabolism of induced mammary cancers in rats.
Topics: Animals; Cyclophosphamide; DNA, Neoplasm; Dose-Response Relationship, Drug; Female; Fluorouracil; In | 1978 |
Chemoimmunotherapy of syngeneic mouse mammary carcinomas employing methanol extraction residue.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; BCG Vaccine; Cyclophosphamide; Female; Fluorouracil; | 1976 |
Effects of nutrition on tumor growth and tolerance to chemotherapy.
Topics: Animals; Body Weight; Diet; Female; Fluorouracil; Glucose; Mammary Neoplasms, Experimental; Neoplasm | 1975 |
Comparison of adjuvant chemotherapeutic activity against primary and metastatic spontaneous murine tumors.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Doxorubicin; Drug Therapy, Combination; Female; Fluo | 1977 |
Enhancement and inhibition of mammary tumor formation and growth by cytostatic drugs.
Topics: Animals; Antineoplastic Agents; Cyclophosphamide; Female; Fluorouracil; Mammary Neoplasms, Experimen | 1977 |
The effect of Corynebacterium parvum in combination with 5-fluorouracil, L-phenylalanine mustard, or methotrexate on the inhibition of tumor growth.
Topics: Animals; Cell Division; Cyclophosphamide; Drug Synergism; Female; Fluorouracil; Immunotherapy; Mamma | 1976 |
Effects of differential hypothermia and 5-fluorouracil on C3H mouse mammary tumors: histologic study.
Topics: Animals; Cryosurgery; Fluorouracil; Hypothermia, Induced; Mammary Glands, Animal; Mammary Neoplasms, | 1976 |
Biochemical modulation of 5-fluorouracil with leucovorin or delayed uridine rescue. Correlation of antitumor activity with dosage and FUra incorporation into RNA.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Dose-Response Relationship, Dr | 1992 |
Biochemical modulation of tumor cell energy: regression of advanced spontaneous murine breast tumors with a 5-fluorouracil-containing drug combination.
Topics: 6-Aminonicotinamide; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 1992 |
Identification and characterization of osteoclast progenitors by clonal analysis of hematopoietic cells.
Topics: Adenocarcinoma; Animals; Bone Marrow Cells; Cells, Cultured; Colony-Forming Units Assay; Culture Med | 1992 |
1 alpha-hydroxyvitamin D3, hypercalcemia, and growth suppression of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Divi | 1992 |
Intratumor treatment of C3H mouse mammary carcinoma with 5-fluorouracil adsorbed on activated charcoal particles.
Topics: Adenocarcinoma; Adsorption; Animals; Charcoal; Female; Fluorouracil; Mammary Neoplasms, Experimental | 1992 |
Antitumor effect and tumor level of 5-fluoro-2'-deoxyuridylate following oral administration of tetradecyl 2'-deoxy-5-fluoro-5'-uridylate.
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Colonic Neoplasms; Fluorodeoxy | 1992 |
Evaluation of the wap-ras transgenic mouse as a model system for testing anticancer drugs.
Topics: Animals; Antineoplastic Agents; Cyclophosphamide; Disease Models, Animal; Fluorouracil; Genes, ras; | 1992 |
Effect of etoposide, carmustine, vincristine, 5-fluorouracil, or methotrexate on radiobiologically oxic and hypoxic cells in a C3H mouse mammary carcinoma in situ.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma in Situ; C | 1992 |
Hypoxia-induced drug resistance: comparison to P-glycoprotein-associated drug resistance.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, N | 1991 |
Loss of murine tumor thymidine kinase activity in vivo following 5-fluorouracil (FUra) treatment by incorporation of FUra into RNA.
Topics: Animals; DNA; Dose-Response Relationship, Drug; Fluorouracil; Mammary Neoplasms, Experimental; Metho | 1991 |
In vivo monitoring of changes in 5-fluorouracil metabolism induced by methotrexate measured by 19F NMR spectroscopy.
Topics: Animals; Female; Fluorouracil; Magnetic Resonance Spectroscopy; Male; Mammary Neoplasms, Experimenta | 1991 |
Chemoendocrine therapy in DMBA-induced rat mammary carcinoma.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Combined Chemotherapy Protocols; Female; F | 1990 |
Differential effects of 2,2'-anhydro-5-ethyluridine, a uridine phosphorylase inhibitor, on the antitumor activity of 5-fluorouridine and 5-fluoro-2'-deoxyuridine.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Drug Interactions; Floxuridine; Fluorouracil; Humans; Ki | 1990 |
Protein intake and 5-fluorouracil toxicity in tumor-bearing animals.
Topics: Animals; Body Weight; Diarrhea; Dietary Proteins; Female; Fluorouracil; Leukopenia; Mammary Neoplasm | 1990 |
[Metabolic characteristics and antitumor activity of BOF-A2, a new 5-fluorouracil derivative].
Topics: Animals; Antineoplastic Agents; Female; Fluorouracil; Male; Mammary Neoplasms, Experimental; Mice; N | 1990 |
Experimental studies on interactions of radiation and cancer chemotherapeutic drugs in normal tissues and a solid tumour.
Topics: Animals; Antineoplastic Agents; Bleomycin; Carcinoma; Cisplatin; Combined Modality Therapy; Cyclopho | 1986 |
Protective, tumor-selective dual pathway activation of 5-fluoro-2'-deoxycytidine provided by tetrahydrouridine in mice bearing mammary adenocarcinoma-755.
Topics: Animals; Antimetabolites; Chromatography, High Pressure Liquid; Cytidine Deaminase; DCMP Deaminase; | 1987 |
[Reduction of 5-FU toxicity with improved nutritional status in tumor bearing mice].
Topics: Animals; Bone Marrow; Dietary Proteins; Fluorouracil; Interferons; Mammary Neoplasms, Experimental; | 1989 |
[Effects of chemo-endocrine therapy on DMBA-induced rat mammary carcinoma].
Topics: 9,10-Dimethyl-1,2-benzanthracene; Adenocarcinoma; Animals; Drug Evaluation; Drug Therapy, Combinatio | 1989 |
Quantitation of 5-fluorouracil incorporation into RNA by high-performance liquid chromatography without the use of radioactive precursors.
Topics: Animals; Chromatography, High Pressure Liquid; Fluorouracil; Hydrolysis; Mammary Neoplasms, Experime | 1989 |
Transplantable mouse mammary adenocarcinoma 16/c as a model in experimental cancer therapy. III. Sensitivity to antitumor drugs.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 1989 |
Use of oral uridine as a substitute for parenteral uridine rescue of 5-fluorouracil therapy, with and without the uridine phosphorylase inhibitor 5-benzylacyclouridine.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure Liquid; Disea | 1989 |
Nucleoside analogues: 8. Some isomers of B.3839, the original 5-fluorouracil/nitrosourea molecular combination, and their effect on colon, breast and lung tumours in mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Chemical Phenomena; Chemistry; Colonic Neoplasms; Dr | 1989 |
[Antitumor effects of 5-fluorouracil-bound organic silicon compound].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Ethyla | 1989 |
Selective expansion of 5,10-methylenetetrahydrofolate pools and modulation of 5-fluorouracil antitumor activity by leucovorin in vivo.
Topics: Animals; Female; Fluorodeoxyuridylate; Fluorouracil; Leucovorin; Mammary Neoplasms, Experimental; Mi | 1989 |
Nucleoside analogues. 9. Seco-nucleoside analogues of some 5-fluorouracil/nitrosourea molecular combinations having uracil as base: synthesis and anti-tumour activity.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Chemical Phenomena; Chemistry; Colonic Neo | 1989 |
Nucleoside analogues: 7. Effect on colon, breast and lung tumours in mice of 5-fluorouracil/nitrosourea molecular combinations incorporating alkoxy and oxidized sulphur functions.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Drug Combinations; Drug Evaluation, Preclinical; Fluorou | 1989 |
The mechanism of dNTP-unbalanced cell death induced by 5-fluorouracil and its derivatives.
Topics: Animals; Cell Line; Cell Survival; Deoxyribonucleotides; Floxuridine; Fluorouracil; Kinetics; Mammar | 1985 |
[Inhibitory effect of UFT on postoperative lung metastasis of mammary adenocarcinoma in SHR rats].
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Drug Synergism; Female; Flu | 1988 |
Thermochemotherapy in vivo of a C3H mouse mammary carcinoma: single fraction heat and drug treatment.
Topics: Animals; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Female; Fluorouracil; Hype | 1988 |
Studies on 18F-labeled pyrimidines III. Biochemical investigation of 18F-labeled pyrimidines and comparison with 3H-deoxythymidine in tumor-bearing rats and mice.
Topics: Animals; Floxuridine; Fluorouracil; Iron Radioisotopes; Liver Neoplasms, Experimental; Mammary Neopl | 1985 |
Carcinogenesis and aging. VIII. Effect of host age on tumour growth, metastatic potential, and chemotherapeutic sensitivity to 1.4-benzoquinone-guanylhydrazonethiosemicarbazone (ambazone) and 5-fluorouracil in mice and rats.
Topics: Adenocarcinoma; Aging; Animals; Antineoplastic Agents; Cell Division; Female; Fluorouracil; Leukemia | 1988 |
Collagen gel culture of rat mammary tumor cells as an assay system for determination of therapeutic efficacy of chemotherapeutic agents.
Topics: Animals; Collagen; Dose-Response Relationship, Drug; Doxorubicin; Drug Screening Assays, Antitumor; | 1988 |
Basic investigations on interaction of 5-fluorouracil and tumor ischemia in the treatment of liver malignancies.
Topics: Adenocarcinoma; Animals; Combined Modality Therapy; Female; Fluorouracil; Humans; Ischemia; Liver Ne | 1988 |
[Synergistic effect of cell kinetics-directed chemo-endocrine therapy on experimental mammary tumors].
Topics: Androgens; Animals; Cell Cycle; Combined Modality Therapy; Drug Administration Schedule; Drug Therap | 1987 |
[Experimental studies on the enhanced effects of chemoendocrine therapy in breast cancer].
Topics: Animals; Breast Neoplasms; Cell Cycle; Cells, Cultured; Combined Modality Therapy; Drug Synergism; F | 1987 |
[Preclinical and clinical studies of sequential therapy with methotrexate and 5 fluorouracil in breast cancer].
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Adminis | 1986 |
Plasma levels of a viral protein during adjuvant treatment: reflection of murine mammary tumor status and therapeutic effect.
Topics: Animals; Antigens, Neoplasm; Antigens, Viral, Tumor; Antineoplastic Combined Chemotherapy Protocols; | 1986 |
Failure of L-histidinol to improve the therapeutic efficiency of 5-fluorouracil against murine breast tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Cell Cycle; Female; Fluorour | 1987 |
Toxicity of 5-fluorouracil for aerobic and hypoxic cells in two murine tumours.
Topics: Aerobiosis; Animals; Combined Modality Therapy; Fluorouracil; Lung Neoplasms; Mammary Neoplasms, Exp | 1987 |
Therapeutic effect reflected by plasma levels of a viral protein during combination chemotherapeutic treatment of mammary tumor-bearing mice.
Topics: Animals; Antigens, Neoplasm; Antigens, Viral, Tumor; Antineoplastic Combined Chemotherapy Protocols; | 1985 |
Cancer chemotherapy: past is prologue.
Topics: 6-Aminonicotinamide; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy | 1985 |
[Biochemical modulation of 5-FU by thymidine and N-phosphoacetyl-L-aspartate: the relation between 5-FU incorporation into RNA and its cytocidal effect].
Topics: Animals; Aspartic Acid; Cell Division; Cell Survival; Cells, Cultured; DNA, Neoplasm; Drug Synergism | 1986 |
Decreased host toxicity in vivo during chronic treatment with 5-flourouracil.
Topics: Animals; Body Weight; Dihydrouracil Dehydrogenase (NAD+); Drug Administration Schedule; Drug Resista | 1985 |
Comparative radiopharmacokinetics of 18F-5-fluorouracil administered i.v. to rats bearing a mammary tumor.
Topics: Adenocarcinoma; Animals; Female; Fluorine; Fluorouracil; Injections, Intravenous; Kinetics; Mammary | 1985 |
Factors affecting growth and drug sensitivity of mouse mammary tumor lines in collagen gel cultures.
Topics: Animals; Cells, Cultured; Collagen; Colony-Forming Units Assay; DNA, Neoplasm; Female; Fluorouracil; | 1985 |
[The radiosensitizing effects of misonidazole and/or 5FU on C3H mouse mammary carcinoma].
Topics: Animals; Combined Modality Therapy; Female; Fluorouracil; Male; Mammary Neoplasms, Experimental; Mic | 1985 |
Response of solid tumor cells exposed to chemotherapeutic agents in vivo: cell survival after 2- and 24-hour exposure.
Topics: Animals; Antibiotics, Antineoplastic; Bleomycin; Cell Survival; Cyclophosphamide; Female; Fluorourac | 1973 |
Responses of cycling and noncycling cells to 1,3-bis(2-chloroethyl)-1-nitrosourea and to bleomycin.
Topics: Animals; Bleomycin; Carmustine; Cell Division; Cell Survival; Cells, Cultured; Cricetinae; Culture T | 1974 |
Immunotherapeutic studies in mice with the methanol-extraction residue (mer) fraction of BCG: solid tumors.
Topics: Animals; Antigens, Bacterial; BCG Vaccine; Benzopyrenes; Cyclophosphamide; Female; Fibrosarcoma; Flu | 1973 |
[Application of morphological and histochemical methods for evaluation of cytostatic effects on organ cultures of malignant tumors].
Topics: Animals; Antineoplastic Agents; Carcinoma; Culture Techniques; Female; Fluorouracil; Histocytochemis | 1974 |
Antigenicity of C 3 H mammary carcinoma in isogenetic hosts: preliminary studies.
Topics: Animals; Antigens, Neoplasm; Carcinoma; Fluorouracil; Immunologic Techniques; Mammary Neoplasms, Exp | 1973 |
Selective immunosuppression by drugs in balanced immune responses.
Topics: Animals; Antibody Formation; Cell Division; Clone Cells; Cytarabine; Cytotoxicity Tests, Immunologic | 1974 |
Influence of five anti-cancer drugs on the induction and growth of experimental mammary cancers: comparison with ovariectomy.
Topics: Animals; Antineoplastic Agents; Castration; Cyclophosphamide; Female; Fluorouracil; Injections, Intr | 1968 |
Relative effects of varying concentrations of cytotoxic drugs in vitro on tumour and reticulo-endothelial tissue.
Topics: Animals; Antineoplastic Agents; DNA; DNA, Neoplasm; Fluorouracil; Glucose; In Vitro Techniques; Mamm | 1968 |
[Effect of antineoplastic agents on the hypophysis-ovarian system in rats with transplantable mammary neoplasms].
Topics: Adrenal Glands; Animals; Cyclophosphamide; Estrus; Female; Fluorouracil; Mammary Neoplasms, Experime | 1971 |
Enhancement of tumor growth and immunosuppression in mice with 5-fluorouracil.
Topics: Adenocarcinoma; Animals; Female; Fluorouracil; Immunosuppression Therapy; Mammary Neoplasms, Experim | 1972 |
[Isolation of 3 antibiotic substances following administration of 5-fluorouracil].
Topics: Animals; Biological Assay; Chromatography, Paper; Female; Fluorouracil; Kidney; Liver; Mammary Neopl | 1971 |
[Distribution of 5-fluorouracil in the bodies of mice with tumors of different sensitivities to the drug].
Topics: Adenocarcinoma; Animals; Fluorouracil; Kidney; Liver; Mammary Neoplasms, Experimental; Melanoma; Mic | 1970 |
[Submicroscopic changes in the cells of mammary gland adenocarcinoma in mice caused by 5-fluorouracil].
Topics: Adenocarcinoma; Animals; Cell Nucleolus; Cell Nucleus; Endoplasmic Reticulum; Fluorouracil; Mammary | 1970 |
Effect of chemotherapy on uptake of alkali metals by experimental tumors.
Topics: Animals; Azaserine; Carcinoma; Cesium; Cyclophosphamide; Fluorouracil; In Vitro Techniques; Mammary | 1968 |